Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant chemotherapy followed by surgery versus surgery alone for high-risk retroperitoneal sarcoma
NL-OMON52562Phase 3Recruiting
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Feb 2022
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of doxorubicin, ifosfamide and dacarbazine in retroperitoneal sarcoma (RPS), Liposarcoma and leiomyosarcoma (LMS), sponsored by European Organisation for Research and Treatment of Cancer. Started Feb 2022; status: recruiting.
02
Drugs
doxorubicinifosfamidedacarbazine
03
Conditions
retroperitoneal sarcoma (RPS)Liposarcomaleiomyosarcoma (LMS)
Beyond the preview
Go deeper on NL-OMON52562.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52562.